Aptevo Therapeutics, Inc. (APVO)
0.4041
-0.01
(-2.37%)
USD |
NASDAQ |
Nov 20, 16:00
0.415
+0.01
(+2.70%)
After-Hours: 20:00
Aptevo Therapeutics Enterprise Value : -3.202M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | -3.202M |
| November 19, 2026 | -3.176M |
| November 18, 2026 | -3.090M |
| November 17, 2026 | -3.050M |
| November 16, 2026 | -2.816M |
| November 13, 2026 | -2.695M |
| November 12, 2026 | -2.518M |
| November 11, 2026 | -2.251M |
| November 10, 2026 | -1.396M |
| November 09, 2026 | -1.263M |
| November 06, 2026 | -0.9688M |
| November 05, 2026 | -0.8887M |
| November 04, 2026 | -0.6215M |
| November 03, 2026 | -0.6482M |
| November 02, 2026 | -0.6749M |
| October 30, 2026 | -0.7017M |
| October 29, 2026 | -0.6482M |
| October 28, 2026 | -0.8085M |
| October 27, 2026 | -0.862M |
| October 26, 2026 | -0.2742M |
| October 23, 2026 | 0.0198M |
| October 22, 2026 | 0.0198M |
| October 21, 2026 | -0.007M |
| October 20, 2026 | 0.0331M |
| October 19, 2026 | -0.007M |
| Date | Value |
|---|---|
| October 16, 2026 | 0.0465M |
| October 15, 2026 | 0.2602M |
| October 14, 2026 | 0.3404M |
| October 13, 2026 | 0.3404M |
| October 12, 2026 | 0.6244M |
| October 09, 2026 | 0.5007M |
| October 08, 2026 | 0.5274M |
| October 07, 2026 | 0.6343M |
| October 06, 2026 | 0.5141M |
| October 05, 2026 | 0.5274M |
| October 02, 2026 | 0.4205M |
| October 01, 2026 | 0.4205M |
| September 30, 2026 | 0.5809M |
| September 29, 2026 | -2.949M |
| September 28, 2026 | -2.878M |
| September 25, 2026 | -2.906M |
| September 24, 2026 | -2.991M |
| September 23, 2026 | -2.906M |
| September 22, 2026 | -2.963M |
| September 21, 2026 | -3.020M |
| September 18, 2026 | -2.977M |
| September 17, 2026 | -2.977M |
| September 16, 2026 | -3.147M |
| September 15, 2026 | -3.162M |
| September 14, 2026 | -3.034M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oncolytics Biotech, Inc. | 44.27M |
| Sangamo Therapeutics, Inc. | 35.66M |
| Sarepta Therapeutics, Inc. | 1.604B |
| Anixa Biosciences, Inc. | 69.43M |
| Vicapsys Life Sciences, Inc. | 16.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.549M |
| Total Expenses (Quarterly) | 6.549M |
| EPS Diluted (Quarterly) | -5.191 |
| Earnings Yield | -5.65K% |
| Normalized Earnings Yield | -5647.19 |